Syngene International gains after posting good Q4 results

Syngene International rose 1.53% to Rs 384.35 at 12:55 IST on BSE after net profit rose 18% to Rs 66 crore on 31% rise in revenue to Rs 334 crore in Q4 March 2016 over Q4 March 2015.

The result was announced after market hours yesterday, 26 April 2016.

Meanwhile, the S&P BSE Sensex was up 23.76 points or 0.09% at 26,031.06.

Higher than usual volumes were witnessed on the counter. On BSE, so far 53,905 shares were traded in the counter as against average daily volume of 20,282 shares in the past one quarter. The stock hit a high of Rs 392.70 and a low of Rs 380.80 so far during the day. The stock hit a record high of Rs 435.60 on 5 January 2016. The stock hit a 52-week low of Rs 295 on 11 August 2015. The stock had underperformed the market over the past one month till 26 April 2016, falling 1.3% compared with Sensex's 2.64% rise. The scrip had also underperformed the market in past one quarter, dropping 4.62% as against Sensex's 6.21% rise.

The mid-cap company has equity capital of Rs 200 crore. Face value per share is Rs 10.

Syngene International's earnings before interest, tax, depreciation and amortization (EBITDA) margin dropped to 32% in Q4 March 2016 from 34% in Q4 March 2015. EBITDA rose 23% to Rs 106 crore in Q4 March 2016 over Q4 March 2015. During Q4 March 2016, the company recorded a broad based growth across all the three verticals-dedicated R&D centres, discovery services and development & manufacturing services.

Syngene International got listed on the bourses on 11 August 2015.

Promoted by Biocon, Syngene International is a leading India-based contract research organization (CRO) offering a suite of integrated and end-to-end discovery and development services for novel molecular entities (NMEs) across industrial sectors. Biocon holds 72.61% stake in Syngene, as per the shareholding pattern as on 31 March 2016.

Powered by Capital Market - Live News